Sorrento Therapeutics
Sorrento Therapeutics
SRNE
OTC
0.01
USD
0.00%
About
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics.
The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec).
The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 172.6K |
| Three Month Average Volume | 2.6M |
| High Low | |
| Fifty-Two Week High | 0.2495 USD |
| Fifty-Two Week Low | 0.0001 USD |
| Fifty-Two Week High Date | 22 Dec 2023 |
| Fifty-Two Week Low Date | 24 Apr 2024 |
| Price and Volume | |
| Current Price | 0.006 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -43.21% |
| Thirteen Week Relative Price Change | -50.39% |
| Twenty-Six Week Relative Price Change | -72.72% |
| Fifty-Two Week Relative Price Change | -96.38% |
| Year-to-Date Relative Price Change | -95.90% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -46.90% |
| Twenty-Six Week Price Change | -70.00% |
| Five Day Price Change | -25.93% |
| Fifty-Two Week Price Change | -95.46% |
| Year-to-Date Price Change | -95.14% |
| Month-to-Date Price Change | -20.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.03611 USD |
| Book Value Per Share (Most Recent Quarter) | -0.37725 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.4576 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.74978 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.66069 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.14986 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.12623 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.36614 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.0868 USD |
| Normalized (Last Fiscal Year) | -1.11512 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.36614 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.0868 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.36614 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.0868 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.097 USD |
| Cash Per Share (Most Recent Quarter) | 0.1483 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.30233 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.07657 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.47768 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -523 |
| Cash Flow Revenue (Trailing Twelve Months) | -378 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -860.05% |
| Pretax Margin (Last Fiscal Year) | -893.95% |
| Pretax Margin (5 Year) | -915.85% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 46.77% |
| Gross Margin (Trailing Twelve Months) | 44.57% |
| Gross Margin (5 Year) | 63.66% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -759.57% |
| Operating Margin (Trailing Twelve Months) | -734.68% |
| Operating Margin (5 Year) | -781.18% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -890.10% |
| Net Profit Margin (Trailing Twelve Months) | -874.54% |
| Net Profit Margin (5 Year) | -894.40% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 31.10% |
| Revenue Growth (3 Year) | -16.18% |
| Revenue Change (Trailing Twelve Months) | 16.89% |
| Revenue Per Share Growth | -41.34% |
| Revenue Growth (5 Year) | 25.98% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 4.48% |
| Total Debt (5 Year) | 46.71% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 68.20% |
| EPS Change (Trailing Twelve Months) | 29.05% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 61.5M |
| Net Debt (Last Fiscal Year) | -14,562,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 0 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -307,514,000 |
| Free Cash Flow (Trailing Twelve Months) | -243,212,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -4 |
| Net Interest Coverage (Trailing Twelve Months) | -5 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -95.80% |
| Return on Assets (Trailing Twelve Months) | -103.24% |
| Return on Assets (5 Year) | -65.05% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -1,904.94% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -288.42% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -158.91% |
| Return on Investment (Trailing Twelve Months) | -168.37% |
| Return on Investment (5 Year) | -80.35% |